By: Miranda Schwartz
Novo Nordisk has recently filed a patent infringement lawsuit in New Jersey Federal Court against Genentech, Eli Lilly, Pharmacia & Upjohn and Serono corporations. The companies all make and/or sell biosynthetic human growth hormone products that compete with Novo’s Norditropin.
This is not the first time Novo has had patent problems. Norditropin was approved by the FDA in May 1995, but due to patent litigation between Novo and Genentech, it was not launched until February 1997.
Novo says its patent is infringed on by Genentech’s Nutropin and Nutropin AQ, Lilly’s Humatrope, P&U’s Genotropin and Serono’s Serostim and Saizen products. Lilly is also accused of two additional patent infringements.